Healthcare | August 13, 2021
HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Substantial reduction in losses
Substantial reduction in losses
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
Subscribe To Our Newsletter & Stay Updated
